

Central Lancashire Online Knowledge (CLoK)

Title	Measures Associated With Early, Late, and Persistent Clinically Significant				
	Symptoms of Depression 1 Year After Stroke in the AFFINITY Trial				
Type	Article				
URL	https://clok.uclan.ac.uk/id/eprint/40553/				
DOI	https://doi.org/10.1212/wnl.00000000000058				
Date	2022				
Citation	Almeida, Osvaldo P., Hankey, Graeme J., Ford, Andrew Hugh, Etherton-Beer, Christopher, Flicker, Leon and Hackett, Maree (2022) Measures Associated With Early, Late, and Persistent Clinically Significant Symptoms of Depression 1 Year After Stroke in the AFFINITY Trial. Neurology, 98 (10). ISSN 0028-3878				
Creators	Almeida, Osvaldo P., Hankey, Graeme J., Ford, Andrew Hugh, Etherton-Beer, Christopher, Flicker, Leon and Hackett, Maree				

It is advisable to refer to the publisher's version if you intend to cite from the work. https://doi.org/10.1212/wnl.00000000000008

For information about Research at UCLan please go to http://www.uclan.ac.uk/research/

All outputs in CLoK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the http://clok.uclan.ac.uk/policies/

eTable 2. Risk ratio of stroke participants showing evidence of clinically significant symptoms of depression[‡] over a period of 52 weeks according to their baseline characteristics (using

doubling of NIHSS scores rather than mRS as a measure of severity of stroke).

		Early depression N=227 RR (95%CI) [†]	Late depression N=87 RR (95%CI)	Persistent depression N=136 RR (95%CI)
Age in years	< 60 60-69 ≥ 70	1 (Reference) 1.09 (0.74-1.60) 1.06 (0.70-1.61)	1 (Reference) 0.80 (0.44-1.46) 1.12 (0.64-1.99)	1 (Reference) 0.91 (0.55-1.53) 1.38 (0.84-2.26)
Female sex		1.28 (0.91-1.81)	1.59 (0.98-2.58)	1.41 (0.93-2.15)
Marital status not	t married or partnered	0.67 (0.41-1.09)	0.55 (0.26-1.16)	0.29 (0.14-0.61)
Living alone		1.51 (0.80-2.87)	0.90 (0.35-2.29)	1.56 (0.66-3.65)
Country	Vietnam Australia / New Zealand	1 (Reference) 1.72 (1.15-2.58)	1 (Reference) 4.29 (2.45-7.52)	1 (Reference) 3.94 (2.42-6.41)
Mild to moderate	disability pre-stroke	1.90 (0.76-4.80)	2.37 (0.79-7.12)	1.38 (0.42-4.52)
Stroke classification	POCS Haemorrhagic LACS PACS TACS Uncertain*	1 (Reference) 1.26 (0.71-2.23) 1.78 (1.06-2.99) 0.85 (0.53-1.39) 1.25 (0.59-2.68)	1 (Reference) 1.74 (0.74-4.11) 1.34 (0.57-3.15) 1.64 (0.81-3.32) 3.19 (1.22-8.38) 3.67 (0.32-42.24)	1 (Reference) 0.63 (0.30-1.33) 0.77 (0.39-1.53) 0.93 (0.54-1.59) 1.10 (0.47-2.60) 1.48 (0.13-16.52)
Doubling of NIH	SS	2.08 (1.65-2.62)	1.53 (1.14-2.06)	2.50 (1.89-3.32)
Depression bet treatment	fore stroke requiring	1.41 (0.52-3.84)	1.90 (0.65-5.57)	6.28 (2.88-13.71)
Assigned treatment with placebo [#]		1.10 (0.80-1.51)	0.92 (0.58-1.46)	1.23 (0.824-1.83)

[‡]Clinically significant symptoms of depression defined by a total PHQ-9 score ≥ 9 or participant reported clinician diagnosis of depression or introduction of an antidepressant during the study or referral for non-pharmacological treatment of depression. A total of 771 (63.1%) participants showed no evidence of depression over 52 weeks. The analyses were limited to the 1159 participants who were alive and had not been lost by week 52.

95%CI: 95% confidence interval.

mRS: Modified Rankin Scale.

LACS: Lacunar stroke; PACS: Partial Anterior Circulation stroke; POCS: Posterior Circulation stroke; TACS: Total Anterior Circulation stroke

[†]Risk ratio (RR) derived multinominal logistic regression. All listed measures were entered simultaneously in the model and the reported risk ratios indicate the main effect of the exposures. Bold print used to highlight statistically significant associations.

^{*}Uncertain includes 3 cases with unrecorded classification and 4 whose diagnosis of stroke was questionable.

^{*}Participants were randomly assigned treatment with fluoxetine or placebo for 26 weeks (6 months).